ArticleInternational journal of clinical pharmacy2025
Opioid prescribing prevalence and initiation rates in Victoria, Australia: insights from primary care data during a period of opioid policy changes (2017-2022).
Article in International journal of clinical pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bacillus coagulans TBC169 probiotics for intestinal function recovery after gynecological open surgery: a randomized, double-blind, placebo-controlled trial.International journal of clinical pharmacy · 2025Trial
- What influences Australian pharmacists' decisions to supply opioids? Results from a survey and randomised controlled factorial experiment.Drug and alcohol review · 2025Trial
- The constant conflicts of opioid prescribing - GPs' views on treating chronic pain with opioids in primary care: a reflexive qualitative analysis.Scandinavian journal of primary health care · 2026Article
- Understanding the first prescription: clinical and demographic drivers of strong opioid use in primary care.Pain medicine (Malden, Mass.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOpioid medications are widely prescribed for acute, chronic and cancer pain. In Australia, opioid prescribing rates remain high.
aimThis study aimed to document patterns of primary care opioid prescribing from 2017 to 2022 by demographic characteristics in Victoria, Australia.
methodThis study was a retrospective descriptive analysis, examining prescribing data sourced from the population level analysis and reporting general practice analytics platform. We examined monthly opioid prescription and initiation rates across diverse demographic factors such as age, gender, socioeconomic status (SES), and geographical location. Poisson regression was used to calculate rate ratios for the incidence of opioid initiation over time, adjusting for age, gender, and SES.
resultsBetween 2017 and 2022, tapentadol prescriptions increased by 263%, while prescription rates for other opioids declined. Females accounted for 53% of opioid prescriptions, but males had higher initiation rates. Initiation rates declined across most demographics, except for the 15-24 age group, which experienced a 69% increase. Socioeconomically disadvantaged and regional/remote populations showed higher prescribing rates but significant declines over time.
conclusionThis study contributes valuable insights into the prescribing trends in primary health settings. The findings suggest targeted interventions to address socioeconomic and regional disparities are needed, to ensure the quality use of opioids across diverse populations.
Indexed as
Identifiers
39718760What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.